However, Cdx2 expression in gastric cancer was associated with biologically aggressive phenotypes such as sex (pooled RR=1.27, 95% CI: 1.17–1.38, P<0.00001 fixed-effect), clinical stage (pooled RR=1.63, 95% CI: 1.42–1.87, P<0.00001 fixed-effect), tumor differentiation (pooled RR=1.54, 95% CI: 1.34-1.76, P<0.00001 fixed-effect), vascular invasion (pooled RR=1.23, 95% CI: 1.08-1.41, P=0.002 fixed-effect) and lymph node metastasis (pooled RR=1.52, 95% CI: 1.33-1.73, P<0.00001 fixed-effect). Here, CDX2 is linked to metastatic malignant neoplasm in the lymph nodes.